Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
M-Vax plus low-dose interleukin-2 versus placebo vaccine plus low-dose interleukin-2 in stage IV melanoma
2007-004406-26Phase 3Completed
- Sponsor
- AVAX Technologies, Inc.
- Start
- Sep 2007
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 3, randomised trial in melanoma comparing M-Vax + low-dose interleukin-2 with Placebo vaccine + low-dose interleukin-2 (2 arms). Primary endpoint: Best overall anti-tumor response rate. Started Sep 2007; status: completed.
02
Drugs
M-Vax
03
Conditions
melanoma
Beyond the preview
Go deeper on 2007-004406-26.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2007-004406-26.